You are here:

levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)

Advice

Following a resubmission

levetiracetam (Keppra) is accepted for use within NHS Scotland as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.

In the pivotal study, addition of levetiracetam to existing anticonvulsant therapy was more effective than addition of placebo in reducing the number of days on which myoclonic seizures occurred.

Drug Details

Drug Name: levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 395/07
Manufacturer: UCB Pharma Ltd
Indication: adjunctive therapy in treatment of myclonic seizures in adults and adolescents from 12 years of age with juvenile muclonic epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 11 February 2008

Archived Advice

Full submission 10 September 2007

Back